Safety Study of PRLX 93936 in Patients With Advanced Solid Tumors
NCT00528047
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
37
Enrollment
INDUSTRY
Sponsor class
Conditions
Cancer
Interventions
DRUG:
PRLX 93936
Sponsor
Prolexys Pharmaceuticals